Latest news with #Wegovy®
Yahoo
22-05-2025
- Health
- Yahoo
Hims & Hers Introduces 6-Month Wegovy® New Customer Offer
SAN FRANCISCO, May 22, 2025--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) today announced eligible customers can access 6 months of prescription-only Wegovy® at a new, affordable price, making proven obesity care and treatments more accessible, more affordable, and more connected for millions of Americans. "We are always looking for long-term, sustainable ways to increase access to care for our customers," said Andrew Dudum, CEO and co-founder of Hims & Hers. "This is another example of how we're working together with the industry to bring people closer to the care and treatments they need." Starting today, new customers eligible for Wegovy® on the Hims & Hers platform can access their care for $549 per month for 6 months (for a limited-time only)1, ensuring customers have a longer window to access the affordable care they need. Included in that price is access to Hims & Hers' world-class, holistic approach to weight loss, powered by today's technology. Hims & Hers will continue to offer access to its full breadth of weight loss treatment options, including other medications, oral kits, protein, nutrition kits, and clinically-backed care plans, all of which help customers start and sustain their health journey based on their needs, goals, and eligibility. For more information, visit About Hims & Hers Health, Inc Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That's why we're building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit and 1 Promo ends 6/30/25. New Wegovy®, first-order customers only, paid up front in full. Savings vary by plan purchase. Discount based on Wegovy® average monthly retail price (w/o insurance). Standard rates resume after promo period: $649/mo (3-mo), $599/mo (6-mo). Auto-renews at standard rates unless canceled 2 days before billing. Rx required. Terms apply. Not available in all 50 states. Weight Loss by Hims & Hers is a holistic program that includes nutrition support, technological tools, and medications prescribed based on what your provider determines is medically appropriate and necessary for you. See website for full details, important safety information, and restrictions, including online provider consultation requirements. View source version on Contacts Press Contact Abby Reisinger-Moleypress@
Business Wire
22-05-2025
- Health
- Business Wire
Hims & Hers Introduces 6-Month Wegovy® New Customer Offer
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) today announced eligible customers can access 6 months of prescription-only Wegovy® at a new, affordable price, making proven obesity care and treatments more accessible, more affordable, and more connected for millions of Americans. 'We are always looking for long-term, sustainable ways to increase access to care for our customers,' said Andrew Dudum, CEO and co-founder of Hims & Hers. 'This is another example of how we're working together with the industry to bring people closer to the care and treatments they need.' Starting today, new customers eligible for Wegovy® on the Hims & Hers platform can access their care for $549 per month for 6 months (for a limited-time only) 1, ensuring customers have a longer window to access the affordable care they need. Included in that price is access to Hims & Hers' world-class, holistic approach to weight loss, powered by today's technology. Hims & Hers will continue to offer access to its full breadth of weight loss treatment options, including other medications, oral kits, protein, nutrition kits, and clinically-backed care plans, all of which help customers start and sustain their health journey based on their needs, goals, and eligibility. For more information, visit About Hims & Hers Health, Inc Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That's why we're building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit and 1 Promo ends 6/30/25. New Wegovy®, first-order customers only, paid up front in full. Savings vary by plan purchase. Discount based on Wegovy® average monthly retail price (w/o insurance). Standard rates resume after promo period: $649/mo (3-mo), $599/mo (6-mo). Auto-renews at standard rates unless canceled 2 days before billing. Rx required. Terms apply. Not available in all 50 states. Weight Loss by Hims & Hers is a holistic program that includes nutrition support, technological tools, and medications prescribed based on what your provider determines is medically appropriate and necessary for you. See website for full details, important safety information, and restrictions, including online provider consultation requirements.
Yahoo
22-05-2025
- Health
- Yahoo
LifeMD Collaborates with Novo Nordisk to Launch $299 Introductory Bundle for Self-Pay Patients Prescribed Wegovy®
Bundled Offer Includes Wegovy® at $199 and LifeMD's Virtual Weight Loss Program for a Total First-Month Cost of $299, $599 per Month Thereafter NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced a limited-time $299 introductory bundle for new self-pay patients prescribed Wegovy® (semaglutide), which includes both the medication and access to LifeMD's virtual weight management program. As part of its collaboration with Novo Nordisk announced last month, LifeMD is offering Wegovy® at a discounted price of $199 for eligible patients through its recently completed integration with NovoCare® Pharmacy, with an additional $100 covering LifeMD's clinical care, onboarding, and ongoing support. The collaboration with Novo Nordisk strengthens LifeMD's ability to deliver branded GLP-1 medications through a fully integrated care experience, addressing the needs of the growing number of self-pay patients seeking FDA-approved replacements for compounded therapies. LifeMD's platform provides an end-to-end model—from virtual consultation to prescription fulfillment to ongoing coaching and support—ensuring continuity of care at every stage of the weight loss journey. The $299 bundle is available to eligible patients prescribed Wegovy® on or before June 30, 2025. Beginning with the second month, the program will cost $599 per month, with no long-term commitment required. 'Our collaboration with Novo Nordisk reflects LifeMD's commitment to improving affordability, convenience, and access for patients seeking medically guided weight loss,' said Justin Schreiber, Chairman and CEO of LifeMD. 'This bundled solution provides a seamless, affordable on-ramp to FDA-approved GLP-1 therapy—replacing the fragmented and often inconsistent experience many patients have faced with compounded alternatives. We look forward to expanding this collaboration to reach more patients and drive better outcomes at scale.' 'Novo Nordisk continues to work with LifeMD to expand access to authentic, FDA-approved Wegovy®, a proven therapy for chronic weight management along with a reduced calorie diet and increased physical activity,' said Dave Moore, Executive Vice President, US Operations of Novo Nordisk Inc. 'This collaboration enables patients to begin their treatment journey through a trusted virtual care platform. We look forward to this collaboration and improving access and outcomes for patients nationwide.' LifeMD's weight management program delivers personalized, clinically guided care for patients across the U.S. By leveraging its vertically integrated platform—including a 50-state medical group and national diagnostic lab partnerships—LifeMD offers a seamless experience from consultation through prescription fulfillment and ongoing support. To learn more about LifeMD's $299 introductory bundled offering with Wegovy®, please visit Wegovy® is the first GLP-1 therapy approved in the United States for both chronic weight management and cardiovascular risk reduction in adults with obesity. Through this offering, all doses of Wegovy® are available in an injector pen – by prescription – to eligible LifeMD patients who are uninsured or whose insurance does not cover prescription weight-loss medications. About LifeMD, Inc. LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men's and women's health, weight management, and hormone therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a 22,500-square-foot affiliated pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit Cautionary Note Regarding Forward Looking Statements This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: 'believe,' 'expect,' 'anticipate,' 'project,' 'should,' 'plan,' 'will,' 'may,' 'intend,' 'estimate,' 'predict,' 'continue,' and 'potential,' or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition. Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, 'Risk Factors' identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods. Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation. Investor Contact:Marc Benathen, Chief Financial Officermarc@ Media Contact:Jessica Friedeman, Chief Marketing Officerpress@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
14-05-2025
- Health
- Business Wire
Found Expands GLP-1 Access With Industry-Leading Formulary and Affordability
MIAMI--(BUSINESS WIRE)-- Found, the leading specialized weight care telehealth platform developed by obesity specialists, today announced it will offer Wegovy® at $499 per month and Zepbound™ vials ranging from $349 to $699. These offerings are made available by prescribing to the innovative direct-to-consumer options developed by Novo Nordisk and Eli Lilly respectively: NovoCare Pharmacy & LillyDirect Pharmacy Solutions. This expansion creates one of the most comprehensive medication formularies in weight care telehealth, with Found clinicians now able to prescribe from more than 15 different medications to deliver personalized care at any budget. "Making these innovative treatments from Novo Nordisk and Eli Lilly more accessible and affordable is a significant step forward for our members," said Found Head of Medical Affairs Rekha Kumar, MD, MS. Found clinicians have been prescribing medications from both Novo Nordisk and Eli Lilly since 2022, building industry-leading expertise in how to maximize their effectiveness for sustainable results. To date, this has been primarily for patients using insurance to cover medications. These new offerings are specifically targeted to expand access to those who haven't been able to afford them without insurance coverage. Unlike platforms focused solely on medication access and delivery, Found integrates these treatments within a comprehensive care model validated by peer-reviewed research. "Since launching in 2019, we've recognized that effective weight care must be as unique as the individuals we serve," said Found CEO Luca Ranaldi. "Our growing formulary addresses the reality that weight care is not one-size-fits-all. By offering multiple medication options and payment solutions, we're building on our long-standing commitment to meet members where they are and provide care tailored to their unique biology, goals, and circumstances." "Making these innovative treatments from Novo Nordisk and Eli Lilly more accessible and affordable is a significant step forward for our members," said Found Head of Medical Affairs Rekha Kumar, MD, MS. "By bringing together these FDA-approved medications with Found's personalized care approach, we're helping more people achieve their health goals affordably, particularly those who may not have insurance coverage for GLP-1s. This expanded access reinforces our commitment to providing comprehensive, effective treatment options that drive real, lasting results." Found's industry-leading formulary delivers several benefits: More Treatment Options: Found clinicians can now prescribe from more than 15 different medications, creating even more personalized treatment plans More Affordable Care: Wegovy® at $499 monthly (60% off retail) and Zepbound™ starting at $349 makes quality care more accessible Complete Support: Members receive ongoing care from specialized clinicians, dedicated coaching, and practical tools that address multiple aspects of weight management Found bridges biology and behavior change through its comprehensive platform, which includes access to one of the industry's most extensive medication formularies, clinical oversight from clinicians trained in obesity medicine, dedicated care team support, one-on-one lifestyle and behavioral coaching, and built-in progress tracking tools. "Our long-standing history prescribing products from Novo Nordisk and Eli Lilly reflects our shared commitment to responsible care," added Ranaldi. "We're committed to strengthening these relationships to help more people access affordable, effective weight care." About Found Found is a physician-designed weight care platform transforming the way society approaches personalized weight management. Founded in 2019, Found provides members with one of the industry's largest medication formularies alongside judgment-free, evidence-based care that combines medication and behavior change support. This comprehensive approach drives lasting results while reducing costs for consumers, employers, and payors. Named one of the best weight loss programs in the United States by Forbes and USA Today, Found is also a member of the Strategies to Overcome and Prevent (STOP) Obesity Alliance. For more information, visit their website.
Yahoo
02-05-2025
- Health
- Yahoo
FDA accepts filing application for oral semaglutide 25 mg, which if approved, would be the first oral GLP-1 treatment for obesity
Novo Nordisk hopes to expand Wegovy® label by becoming the first GLP-1 treatment for obesity in a pill The FDA filing is based on the results of the phase 3 OASIS 4 trial that evaluated oral semaglutide 25 mg in adults with obesity or overweight1 Novo Nordisk continues to build on 100-year-plus legacy of science and innovation PLAINSBORO, N.J., May 2, 2025 /PRNewswire/ -- Today, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) submission for an investigational once-daily, 25 mg oral formulation of Wegovy® (semaglutide) for chronic weight management in adults living with obesity or overweight with one or more comorbid conditions and to reduce the risk of major adverse cardiovascular events (MACE) in adults with overweight or obesity and established cardiovascular disease.2 If approved, Wegovy® would become the first oral formulation of a GLP-1 indicated for chronic weight management. "We are entering a new era of obesity care where patients want individualized treatment plans that address their needs and provide choices, including oral formulations," said Anna Windle, PhD, Senior Vice President, Clinical Development, Medical & Regulatory Affairs at Novo Nordisk Inc. "Novo Nordisk's strong legacy in obesity care and decades of scientific research and innovation have brought us to this moment. We are pleased that the FDA has accepted our submission and look forward to working with regulatory authorities on what would be the first oral GLP-1 treatment for obesity." The FDA application is based on results from OASIS 4, a 64-week phase 3 randomized, controlled trial evaluating the efficacy and safety of once-daily oral semaglutide 25 mg versus placebo in 307 adults with obesity (BMI >/= 30 kg/m2) or overweight (BMI >/= 27 kg/m2) with one or more comorbidities.1,3 Patients with diabetes were excluded.1,3 OASIS 4 included a 64-week treatment period including a 12-week dose escalation, and a 7-week off-treatment follow-up period.1,3 In total, 307 participants were randomized 2:1 ratio to once-daily oral semaglutide 25 mg or placebo, as an adjunct to lifestyle intervention for 64 weeks.1,3 The FDA action date to decide on the Wegovy® oral formulation NDA will be in Q4 2025.2 About Wegovy®Wegovy® (semaglutide) injection 2.4 mg is currently approved along with a reduced calorie diet and increased physical activity, for adults and children aged 12 years and older with obesity, or some adults with overweight who also have weight-related medical problems, to help them lose excess body weight and keep the weight off and to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and either obesity or overweight.4 About obesityObesity is a serious chronic, progressive, and misunderstood disease that requires long-term management.5-7 One key misunderstanding is that this is a disease of just lack of willpower, when in fact there is underlying biology that may impede people with obesity from losing weight and keeping it off.5,7 Obesity is influenced by a variety of factors, including genetics, social determinants of health, and the environment.8,9 The prevalence of overweight and obesity is a public health issue that has severe cost implications to healthcare systems.10,11 In the U.S., about 40% of adults live with obesity.12 About Novo Nordisk Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a US presence spanning 40 years, Novo Nordisk US is headquartered in New Jersey and employs over 10,000 people throughout the country across 12 manufacturing, R&D and corporate locations in eight states plus Washington DC. For more information, visit Facebook, Instagram, and X. Contacts for further information Media:Liz Skrbkova (US)+1 609 917 0632NNIMediaTeam@ Ambre James-Brown (Global)+45 3079 9289Globalmedia@ Investors:Frederik Taylor Pitter (US) +1 609 613 0568fptr@ Jacob Martin Wiborg Rode (Global)+45 3075 5956jrde@ Sina Meyer (Global) +45 3079 6656 azey@ Ida Schaap Melvold (Global) +45 3077 5649 idmg@ Max Ung (Global)+45 3077 6414mxun@ References Garvey W, Duque do Vale R, Karlsson T, et al. Efficacy and Safety of Oral Semaglutide 25 mg in Adults With Overweight/Obesity: The OASIS 4 RCT. Oral presentation presented at ObesityWeek® 2024; 3-6 November 2024; Henry B. Gonzalez Convention Center, San Antonio, US. Presentation Oral-108. Oral Semaglutide 25 mg FDA NDA filing; Novo Nordisk data on file. Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Works in People Who Have a Body Weight Above the Healthy Range (OASIS 4). Last accessed: May 2025. Available at: Wegovy® (semaglutide) injection 2.4 mg Prescribing Information. Plainsboro, NJ: Novo Nordisk Inc.; 2025. Kaplan LM, Golden A, Jinnett K, et al. Perceptions of barriers to effective obesity care: results from the national action study. Obesity. 2018;26(1):61-69. Bray GA, Kim KK, Wilding JPH; World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Rev. 2017;18(7):715-723. Garvey WT, Mechanick JI, Brett EM, et al. American association of clinical endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22 (Suppl 3):1-203. Centers for Disease Control and Prevention. Adult obesity facts. Last accessed: May 2025. Available at: Centers for Disease Control and Prevention. Risk Factors for Obesity. Last accessed: May 2025. Available at: World Obesity Federation. World Obesity Atlas 2023. Last accessed: May 2025. Available at: Centers for Disease Control and Prevention. Why it matters. Last accessed: May 2025. Available at: Centers for Disease Control and Prevention. Obesity and Severe Obesity Prevalence in Adults: United States, August 2021–August 2023. Last accessed May 2025. Available at: © 2025 Novo Nordisk All rights reserved. US25SEMO00927 May 2025 View original content to download multimedia: SOURCE NOVO NORDISK INC. Sign in to access your portfolio
